GSK Consumer Healthcare Q1 net up 19 per cent
GlaxoSmithKline Consumer Healthcare on Monday said its net profit rose 19.3 per cent to Rs 131.97 crore for the first quarter ended March 31.
The company had posted net profit of Rs 110.62 crore for the same period during the 2010-11 fiscal, it said in a statement.
Net sales of the company rose to Rs 813.02 crore for the first quarter ended March 31, 2012, as against Rs 710.01 crore in Q1 last year.
Managing director Zubair Ahmed said, "The company has shown consistent double-digit growth over the years and the results of this quarter are also in line with the company's strong performance."
The company is continuously focusing on innovation and leveraging science to develop products, he added.
Along with these, cost efficiency initiatives and increased penetration across categories have helped the company deliver better results, Ahmed said.
The company makes and markets various products such as Boost, Maltova, Eno, Crocin and Iodex in the country.
Shares of the company closed at Rs 2,701 on the BSE, down 1.70 per cent from its previous close.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
